CA2430577A1 - Composes specifiques aux recepteurs de l'adenosine a1, a2a, et a3 et leurs utilisations - Google Patents

Composes specifiques aux recepteurs de l'adenosine a1, a2a, et a3 et leurs utilisations Download PDF

Info

Publication number
CA2430577A1
CA2430577A1 CA002430577A CA2430577A CA2430577A1 CA 2430577 A1 CA2430577 A1 CA 2430577A1 CA 002430577 A CA002430577 A CA 002430577A CA 2430577 A CA2430577 A CA 2430577A CA 2430577 A1 CA2430577 A1 CA 2430577A1
Authority
CA
Canada
Prior art keywords
compound
receptor
substituted
adenosine
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002430577A
Other languages
English (en)
Inventor
Arlindo L. Castelhano
Bryan Mckibben
David J. Witter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OSI Pharmaceuticals LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/728,316 external-priority patent/US6680322B2/en
Priority claimed from US09/728,616 external-priority patent/US7160890B2/en
Priority claimed from US09/728,607 external-priority patent/US6664252B2/en
Application filed by Individual filed Critical Individual
Publication of CA2430577A1 publication Critical patent/CA2430577A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des composés qui inhibent de manière spécifique les récepteurs de l'adénosine A¿1?, A¿2A?, et A¿3? et l'utilisation de ces composés pour traiter une maladie associées aux récepteurs de l'adénosine A¿1?, A¿2A?, et A¿3? chez un sujet, par administration à ce dernier d'une quantité efficace sur le plan thérapeutique desdits composés.
CA002430577A 2000-12-01 2001-11-30 Composes specifiques aux recepteurs de l'adenosine a1, a2a, et a3 et leurs utilisations Abandoned CA2430577A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US09/728,316 2000-12-01
US09/728,316 US6680322B2 (en) 1999-12-02 2000-12-01 Compounds specific to adenosine A1 receptors and uses thereof
US09/728,616 2000-12-01
US09/728,607 2000-12-01
US09/728,616 US7160890B2 (en) 1999-12-02 2000-12-01 Compounds specific to adenosine A3 receptor and uses thereof
US09/728,607 US6664252B2 (en) 1999-12-02 2000-12-01 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
PCT/US2001/045280 WO2002057267A1 (fr) 2000-12-01 2001-11-30 Composes specifiques aux recepteurs de l'adenosine a1, a2a, et a3 et leurs utilisations

Publications (1)

Publication Number Publication Date
CA2430577A1 true CA2430577A1 (fr) 2002-07-25

Family

ID=27419112

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002430577A Abandoned CA2430577A1 (fr) 2000-12-01 2001-11-30 Composes specifiques aux recepteurs de l'adenosine a1, a2a, et a3 et leurs utilisations

Country Status (20)

Country Link
EP (1) EP1347980A4 (fr)
JP (1) JP4579497B2 (fr)
CN (1) CN1263757C (fr)
AP (1) AP1893A (fr)
AU (1) AU2002248151B2 (fr)
BR (1) BR0115847A (fr)
CA (1) CA2430577A1 (fr)
CZ (1) CZ20031831A3 (fr)
EA (1) EA007254B1 (fr)
HU (1) HUP0400692A3 (fr)
IL (1) IL155962A0 (fr)
ME (1) MEP35308A (fr)
MX (1) MXPA03004717A (fr)
NO (1) NO327207B1 (fr)
NZ (1) NZ525885A (fr)
OA (1) OA13295A (fr)
PL (1) PL363245A1 (fr)
WO (1) WO2002057267A1 (fr)
YU (1) YU42703A (fr)
ZA (1) ZA200303729B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5090531A (en) * 1990-01-10 1992-02-25 Lord Corporation Electrophoretic fluid differential
JP4611524B2 (ja) 1998-06-02 2011-01-12 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ピロロ［２，３ｄ］ピリミジン組成物およびその使用
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
DE10148883A1 (de) * 2001-10-04 2003-04-10 Merck Patent Gmbh Pyrimidinderivate
DK1450811T3 (da) 2001-11-30 2010-02-15 Osi Pharm Inc Forbindelser specifikke af adenosin A1- og A3-receptorer og anvendelser heraf
ATE466581T1 (de) * 2001-12-07 2010-05-15 Vertex Pharma Verbindungen auf pyrimidin-basis als gsk-3-hemmer
US20030229067A1 (en) 2001-12-20 2003-12-11 Arlindo Castelhano Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
CN1620294A (zh) 2001-12-20 2005-05-25 Osi药物公司 嘧啶a2b选择性拮抗剂化合物,它们的合成及用途
WO2004041285A1 (fr) * 2002-10-31 2004-05-21 Amgen Inc. Agents anti-inflammatoires
HUP0203976A3 (en) * 2002-11-15 2004-08-30 Sanofi Aventis Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
ES2344800T3 (es) * 2005-02-18 2010-09-07 Solvay Pharmaceuticals Gmbh Composiciones farmaceuticas que comprenden inhibidores de nep, inhibidores del sistema productor de endotelina endogena y diureticos.
DK3421471T3 (da) 2006-04-25 2021-06-14 Astex Therapeutics Ltd Purin- og deazapurinderivater som farmaceutiske forbindelser
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
TW200808819A (en) * 2006-06-19 2008-02-16 Solvay Pharm Gmbh Use of adenosine A1 antagonists in radiocontrast media induced nephrophaty
PL2201012T3 (pl) 2007-10-11 2014-11-28 Astrazeneca Ab Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b
EP2247596A2 (fr) 2008-01-11 2010-11-10 Natco Pharma Limited Nouveaux derives de pyrazolo [3,4 -d] pyrimidine en tant qu'agents anticancereux
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
EA027506B1 (ru) 2011-04-01 2017-08-31 Астразенека Аб Способ лечения рака молочной железы
HRP20191982T4 (hr) 2011-11-30 2023-01-06 Astrazeneca Ab Kombinacijsko liječenje raka
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
CN104350056A (zh) * 2012-06-07 2015-02-11 霍夫曼-拉罗奇有限公司 端锚聚合酶的吡咯并嘧啶酮和吡咯并吡啶酮抑制剂
SI3010503T1 (sl) 2013-06-21 2020-07-31 Zenith Epigenetics Ltd. Novi biciklični inhibitorji bromodomene
JP6461118B2 (ja) * 2013-06-21 2019-01-30 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． ブロモドメイン阻害剤としての新規の置換された二環式化合物
JP6542212B2 (ja) 2013-07-31 2019-07-10 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． ブロモドメイン阻害剤としての新規キナゾリノン
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
US10179125B2 (en) 2014-12-01 2019-01-15 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
WO2016092375A1 (fr) 2014-12-11 2016-06-16 Zenith Epigenetics Corp. Hétérocycles substitués à titre d'inhibiteurs de bromodomaines
CA2966450A1 (fr) 2014-12-17 2016-06-23 Olesya KHARENKO Inhibiteurs de bromodomaines
EA036122B1 (ru) * 2015-01-20 2020-09-30 Уси Форчун Фармасьютикал Ко., Лтд Ингибитор jak
AU2016254385B2 (en) 2015-04-29 2018-05-10 Wuxi Fortune Pharmaceutical Co., Ltd JAK inhibitors
KR102081272B1 (ko) 2015-05-29 2020-02-25 우시 포춘 파마슈티컬 컴퍼니 리미티드 Janus 키나아제 억제제
CN105771672B (zh) * 2016-04-18 2018-03-02 天津工业大学 一种抗污染抗菌芳香聚酰胺反渗透复合膜及制备方法
EP3594216B1 (fr) * 2017-03-07 2022-04-06 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Composé hétérocyclique à cinq chaînons d'aminopyrimidine, intermédiaire, procédé de préparation, composition pharmaceutique et application de celui-ci
CN108017584B (zh) * 2017-06-20 2021-03-23 南开大学 A3腺苷受体的小分子拮抗剂
CA3100923A1 (fr) * 2018-06-04 2019-12-12 Exscientia Ltd Composes de pyrazolopyrimidine utilises en tant qu'antagonistes du recepteur de l'adenosine
CN110128316B (zh) * 2019-05-22 2021-08-31 北京大学深圳研究生院 5位取代的β-脯氨酸及其衍生物的制备方法
CN110272373B (zh) * 2019-07-02 2022-07-29 天津国际生物医药联合研究院 一种具有选择性的腺苷a1受体拮抗剂及其应用
CN114085178A (zh) * 2021-12-29 2022-02-25 苏州楚凯药业有限公司 一种4-甲基-1-丙基-2-氨基-1h-吡咯-3-腈的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990067704A (ko) * 1992-12-17 1999-08-25 디. 제이. 우드, 스피겔 알렌 제이 부신피질자극호르몬 유리인자 길항제로서의 피롤로피리미딘을함유하는 약학 조성물
US5780450A (en) * 1995-11-21 1998-07-14 Alcon Laboratories, Inc. Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
JP4611524B2 (ja) * 1998-06-02 2011-01-12 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ピロロ［２，３ｄ］ピリミジン組成物およびその使用
HK1050319B (en) * 1999-12-02 2007-04-04 Osi Pharmaceuticals, Inc. Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof
DK1450811T3 (da) * 2001-11-30 2010-02-15 Osi Pharm Inc Forbindelser specifikke af adenosin A1- og A3-receptorer og anvendelser heraf

Also Published As

Publication number Publication date
MEP35308A (en) 2011-02-10
CN1263757C (zh) 2006-07-12
OA13295A (en) 2007-04-13
EA200300628A1 (ru) 2003-12-25
AP1893A (en) 2008-09-23
JP4579497B2 (ja) 2010-11-10
NO20032482L (no) 2003-07-28
WO2002057267A1 (fr) 2002-07-25
EA007254B1 (ru) 2006-08-25
MXPA03004717A (es) 2004-06-30
AP2003002807A0 (en) 2003-06-30
HUP0400692A3 (en) 2007-09-28
EP1347980A4 (fr) 2005-02-09
EP1347980A1 (fr) 2003-10-01
JP2004517896A (ja) 2004-06-17
AU2002248151B2 (en) 2008-02-21
PL363245A1 (en) 2004-11-15
CN1489590A (zh) 2004-04-14
NO20032482D0 (no) 2003-06-02
ZA200303729B (en) 2004-05-14
NO327207B1 (no) 2009-05-11
CZ20031831A3 (cs) 2004-05-12
BR0115847A (pt) 2004-02-25
YU42703A (sh) 2006-03-03
IL155962A0 (en) 2003-12-23
HUP0400692A2 (hu) 2004-07-28
NZ525885A (en) 2005-01-28

Similar Documents

Publication Publication Date Title
CA2430577A1 (fr) Composes specifiques aux recepteurs de l'adenosine a1, a2a, et a3 et leurs utilisations
US6680324B2 (en) Compounds specific to adenosine A1 receptors and uses thereof
US6673802B2 (en) Compounds specific to adenosine A3 receptor and uses thereof
CA2334200C (fr) Compositions de pyrrolo[2,3d]pyrimidine et utilisation
AU784878B2 (en) Compounds specific to adenosine A1 A2A and A3 receptors and uses thereof
US6680322B2 (en) Compounds specific to adenosine A1 receptors and uses thereof
US20020094974A1 (en) Compounds specific to adenosine A3 receptor and uses thereof
US6664252B2 (en) 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
AU2002248151A1 (en) Compounds specific to adenosine A1, A2A, and A3 receptor and uses thereof
CA2468673C (fr) Composes specifiques inhibant les recepteurs a1 et a3 de l'adenosine, et applications desdits composes
US6686366B1 (en) Compounds specific to adenosine A3 receptor and uses thereof
KR100897430B1 (ko) 아데노신 ａ₁, ａ₂ａ 및 ａ₃ 수용체에 특이적인 화합물및 그의 용도

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued